

---

## Hyloris releases Annual Report 2025

Publication Annual Report FY 2025

Annual Shareholders meeting June 9, 2026

Liège, Belgium – 30 April – 05:30 PM CET – Regulated Information – Hyloris Pharmaceuticals SA (“Hyloris”) (Euronext Brussels: HYL), the specialty pharma group committed to addressing unmet medical needs through reinventing existing medications, today announces the publication of its Annual Report for the financial year 2025.

The annual report is available at <https://hyloris.com/2025-annual-report/> and in French and English at <https://hyloris.com/investors-toolkit/> - also including Environmental, Social and Governance (ESG) matters.

Stijn van Rompay, Chief Executive Officer of Hyloris, commented: *“2025 was a year of strong execution for Hyloris, marked by tangible progress across development, partnering, and commercialization. We advanced multiple programs and further strengthened our regional partnerships, positioning the company for sustainable growth. This progress reflects our focused and pragmatic development philosophy, centered on creating differentiated, added-value medicines in a capital-efficient manner.”*

Hyloris also announces that its Annual Shareholders’ Meeting will be held on Tuesday, 9 June 2026, at 02:00 PM CET, at the Company’s registered office: Boulevard Patience & Beaujonc 3/1, 4000 Liège, Belgium. All relevant documents will be made available on the Company’s website on May 8, 2026.

### About Hyloris Pharmaceuticals

Hyloris is a specialty pharma group focused on reinventing and optimizing existing medications through reformulation, repurposing and innovative NCEs to address important healthcare needs and deliver meaningful improvements for patients, healthcare professionals, and payers. The Company’s development strategy primarily focuses on leveraging established regulatory pathways, such as the FDA’s 505(b)(2) pathway in the U.S., or equivalent regulatory frameworks in other regions, which are specifically designed for pharmaceuticals for which safety and efficacy of the molecule have already been established. This approach can reduce the clinical and regulatory burden required for market entry, and significantly shorten development timelines, leading to reduced costs and risks. Hyloris has announced a broad development portfolio of 28 products, including 25 value-added medicines of which two are currently in early stages of commercialization in collaboration with commercial partners: Sotalol IV for the treatment of atrial fibrillation, and Maxigesic® IV, a non-opioid post-operative pain treatment. In addition to its core strategic focus, the Company has two high-barrier generic products approved in the U.S. and one additional high-barrier generic product in development. Beyond its announced portfolio, Hyloris has initiated several additional internal early-stage development activities, bringing the total pipeline to more than 30 products and product candidates, and continues to evaluate further product opportunities to support future growth. **Where others stop, Hyloris starts and adds value through Reinventing Existing Medicines for unmet patient needs worldwide.** Hyloris is based in Liège, Belgium and since 2020 listed on Euronext Brussels (EBR: HYL).

For more information, visit [www.hyloris.com](http://www.hyloris.com) and follow-us on [LinkedIn](#).

---

**Contacts Hyloris Pharmaceuticals :**

Ann De Jaeger, CLO

legal representative of Impact WITH Empathy BV

[Ann.dejaeger@hyloris.com](mailto:Ann.dejaeger@hyloris.com)

32 (0)475 20 13 44 - 32 (0)4 346 02 07

Stijn Van Rompay, CEO

legal representative of SVR Management BV

[stijn.vanrompay@hyloris.com](mailto:stijn.vanrompay@hyloris.com)

32 (0)4 346 02 07

Christophe Maréchal, CFO

legal representative of CMM&C srl

[Christophe.Marechal@hyloris.com](mailto:Christophe.Marechal@hyloris.com)

32 (0)4 346 02 07

**Disclaimer and forward-looking statements**

Hyloris means “high yield, lower risk”, which relates to the 505(b)(2) regulatory pathway for product approval on which the Company focuses, but in no way relates or applies to an investment in the Shares. Certain statements in this press release are “forward-looking statements.” These forward-looking statements can be identified using forward-looking terminology, including the words “believes”, “estimates”, “anticipates”, “expects”, “intends”, “may”, “will”, “plans”, “continue”, “ongoing”, “potential”, “predict”, “project”, “target”, “seek” or “should”, and include statements the Company makes concerning the intended results of its strategy. These statements relate to future events or the Company’s future financial performance and involve known and unknown risks, uncertainties, and other factors, many of which are beyond the Company’s control, that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

This press release contains information about products under development and is not intended as a promotional statement. The products mentioned are subject to regulatory approval and are not currently available for sale. Please consult licensed medical professionals for healthcare decisions.